Engineered lentivector targeting of dendritic cells for in vivo immunization.
about
Recent Advances in Lentiviral Vaccines for HIV-1 InfectionPros and Cons of Antigen-Presenting Cell Targeted Tumor VaccinesTrial watch: Dendritic cell-based anticancer therapyLentiviral vector delivery of human interleukin-7 (hIL-7) to human immune system (HIS) mice expands T lymphocyte populationsVisualization of DC-SIGN-mediated entry pathway of engineered lentiviral vectors in target cellsSuppression of FVIII inhibitor formation in hemophilic mice by delivery of transgene modified apoptotic fibroblasts.Nonintegrating lentiviral vectors can effectively deliver ovalbumin antigen for induction of antitumor immunity.Polymeric Materials for Gene Delivery and DNA VaccinationCell-specific targeting of lentiviral vectors mediated by fusion proteins derived from Sindbis virus, vesicular stomatitis virus, or avian sarcoma/leukosis virus.Recombinant vesicular stomatitis virus transduction of dendritic cells enhances their ability to prime innate and adaptive antitumor immunity.Multiple functions of the 37/67-kd laminin receptor make it a suitable target for novel cancer gene therapyDendritic cell-based human immunodeficiency virus vaccine.Immunization of mice with lentiviral vectors targeted to MHC class II+ cells is due to preferential transduction of dendritic cells in vivoVirus-receptor mediated transduction of dendritic cells by lentiviruses enveloped with glycoproteins derived from Semliki Forest virusTransduction of human antigen-presenting cells with integrase-defective lentiviral vector enables functional expansion of primed antigen-specific CD8(+) T cellsDendritic cell-specific antigen delivery by coronavirus vaccine vectors induces long-lasting protective antiviral and antitumor immunity.Vaccines delivered by integration-deficient lentiviral vectors targeting dendritic cells induces strong antigen-specific immunity.In situ modulation of dendritic cells by injectable thermosensitive hydrogels for cancer vaccines in miceGene carriers and transfection systems used in the recombination of dendritic cells for effective cancer immunotherapy.Dendritic cell-directed vaccination with a lentivector encoding PSCA for prostate cancer in miceImmunization delivered by lentiviral vectors for cancer and infectious diseases.Lentiviral vectors, two decades later.Production of lentiviral vectors with enhanced efficiency to target dendritic cells by attenuating mannosidase activity of mammalian cells.The inside out of lentiviral vectorsConventional dendritic cells are required for the activation of helper-dependent CD8 T cell responses to a model antigen after cutaneous vaccination with lentiviral vectors.A genetically engineered adenovirus vector targeted to CD40 mediates transduction of canine dendritic cells and promotes antigen-specific immune responses in vivoPreferential lentiviral targeting of astrocytes in the central nervous system.Virological and preclinical characterization of a dendritic cell targeting, integration-deficient lentiviral vector for cancer immunotherapyEBV LMP1, a viral mimic of CD40, activates dendritic cells and functions as a molecular adjuvant when incorporated into an HIV vaccine.Classification of current anticancer immunotherapiesHomeostatic cytokines orchestrate the segregation of CD4 and CD8 memory T-cell reservoirs in mice.Suppression of the immune response to FVIII in hemophilia A mice by transgene modified tolerogenic dendritic cellsPseudotyping lentiviral vectors with aura virus envelope glycoproteins for DC-SIGN-mediated transduction of dendritic cells.Enhanced survival and engraftment of transplanted stem cells using growth factor sequestering hydrogels.Construction of stable producer cells to make high-titer lentiviral vectors for dendritic cell-based vaccination.A TLR4 agonist synergizes with dendritic cell-directed lentiviral vectors for inducing antigen-specific immune responsesAntigen targeting to dendritic cells combined with transient regulatory T cell inhibition results in long-term tumor regressionEngineered hepatitis B virus surface antigen L protein particles for in vivo active targeting of splenic dendritic cells.Microparticle surface modifications targeting dendritic cells for non-activating applications.miR-146a controls the resolution of T cell responses in mice.
P2860
Q26742169-11E51BDD-E85E-4109-9053-9001EDC4B9B7Q27013679-60FA629A-D8F5-46CE-B582-317478E82811Q27024047-513ACE5F-46E9-46FD-AFC6-BF88E80DFFB8Q27322228-3191DC6C-3A6D-46CE-B01A-45BED079A11AQ28534404-AA7E85D4-6AF9-4F00-92A5-DE4764266C60Q30493686-2069787B-87BB-4203-BC55-6A3706FF08EBQ33564383-7E9C4921-2901-459E-89EC-DC07BC2BD991Q33565296-E7B51FA2-A2B6-4FB3-9EA9-28FDD0922F0EQ33663063-1611425D-C846-4315-AF30-D49314294B02Q33713903-845EACE5-A719-4A1C-8B85-B0F84050F994Q33730451-153E5F6C-2AAF-40BD-B94E-EF1896B9EE76Q33874652-FF6897D0-310F-4FE0-AF17-CE37C38B3A76Q33945680-521533FD-F945-46EA-8663-956E225A6453Q33954953-4BAC5541-71CE-48A6-8264-8A95F19C3CBFQ34085930-52CD5419-39E8-4B8E-8331-B32C538AA33AQ34128906-AC6108FB-F127-42F1-819D-A222A4F5155CQ34206875-BC1810E7-081F-4445-8982-ACDD8BF13DD9Q34330250-2866C1D1-8558-4073-9707-EFDC6C54E465Q34443707-3417E99A-DB3E-4388-8087-E5F5A1432D13Q34472125-2C033365-B48D-4301-BF9D-4F652266DAB7Q34539879-F4EDD7C7-D655-4A00-AF37-FC531E2C8042Q34539903-DE88B0A7-7C78-4E24-A085-8C86FA04B25FQ34576498-9FD0D02F-A72A-464E-A964-60269E69AA1BQ34633466-4116FFEF-2B95-4362-AA15-EBB3411EB3D6Q34767725-D848B68F-8AA5-49F0-BFC5-3BE3ADAEDCBEQ35005484-4D4DDE82-9636-46D7-8EB3-20C4FF4ED558Q35009241-2627F8A2-3F4B-4924-B782-ABD7497F1452Q35069876-7179B043-F433-40E6-833C-66A802483B20Q35096745-D0C8D260-32B1-4099-A207-407FDDC56796Q35149637-AC931D6F-7C23-4481-8C81-DF1A22F28A10Q35220399-80907A99-DC05-4EC6-B4A1-D8181BA09FC6Q35285735-298C2216-5EA2-4EA1-95B0-9D9BA8CD07DAQ35496414-57152727-FF33-424C-BC1F-35D767B39BF4Q35688529-76F55EBF-3C8E-4AA2-A1D2-598ED3115F55Q35899079-0817BA56-887D-4EC7-BA0E-883BBE190F3AQ35990046-CFD74653-791F-46F3-9071-D535885073FAQ36060263-11BB049D-983E-4D82-A706-74F14EFAA303Q36119591-E1E6125F-B601-4F9B-9234-E739C9504324Q36191163-13EDC3A2-5682-4A0E-9550-BF610F28D391Q36193546-F37370BC-6D97-4DA4-8007-AD142394A72E
P2860
Engineered lentivector targeting of dendritic cells for in vivo immunization.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Engineered lentivector targeting of dendritic cells for in vivo immunization.
@ast
Engineered lentivector targeting of dendritic cells for in vivo immunization.
@en
type
label
Engineered lentivector targeting of dendritic cells for in vivo immunization.
@ast
Engineered lentivector targeting of dendritic cells for in vivo immunization.
@en
prefLabel
Engineered lentivector targeting of dendritic cells for in vivo immunization.
@ast
Engineered lentivector targeting of dendritic cells for in vivo immunization.
@en
P2093
P2860
P356
P1433
P1476
Engineered lentivector targeting of dendritic cells for in vivo immunization.
@en
P2093
Abigail Elliot
Anthony Walls
David Baltimore
Haiguang Yang
Kendra Rideout
Kye Il Joo
Leslie Ziegler
P2860
P2888
P304
P356
10.1038/NBT1390
P577
2008-02-24T00:00:00Z
P5875
P6179
1029715812